Association between CTLA-4 Gene Polymorphism and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients
DOI:
https://doi.org/10.3889/oamjms.2022.9095Keywords:
Polymorphism, CTLA4-1661G>A, Hepatocellular carcinoma, Chronic Hepatitis BAbstract
Introduction:
Hepatocellular carcinoma (HCC) is the most common form of liver cancer; most cases of HCC (approximately 80%) are associated with chronic hepatitis B virus (HBV. The HBV-related incidence of HCC is projected to increase for several decades, because of the high prevalence of chronic HBV infection and prolonged latency to HCC development. As of late, studies concerning the connection between CTLA-4 polymorphisms and a few infections definitely stand out. Associaton CTLA-4- 1661G> A had ever been reported in autoimun cases. But the association of CTLA-4-1661G>A polymorphism with HCC and Chronic Hepatitis B risk is hardly reported.
Method:
The study was conducted in May – November 2020 at Haji Adam Malik General Hospital, Medan, Indonesia. A total of 80 individual were analyzed with case control study. The data analysis was performed with SPSS 18.0 software. Odds ratio (OR) with 95% confidence interval (CI) were used to evaluate the association of CTLA-4 polymorphism with the risk of HCC and Chronic hepatitis B, which was calculated by chi-squared independent test. The examination of CTLA-4 -1661G> polymorphism with real time PCR method. Genomic DNA was extracted from 5 ml frozen whole blood using the DNA Extraction Kit (Qiagen, Germany) according to the manufacturer's protocol.
Result:
The distribution of the characteristics of patients with Hepatocellular Carcinoma(HCC) with a mean age (56.98 ± 12,05) and Hepatitis B (45,95 ± 11,02) with the most orientation for HCC was male(77,5%) and for Chronic Hepatitis B was female (47,5%).The most common BCLC stage in HCC is stage D ( 45%). The result demonstrated that frequencies of hemozyous genotype GG,allele and G were remarkably higher in Hepatocellular Carcinoma Group than Chronic Hepatitis B Group (30% vs 2,5%, 70% vs 97,5%,55% vs 33,75%) while hemozyous genotype GA+AA, allele A were remarkably higher in Chronic Hepatitis B Group than Hepatocellular Carcinoma Group ( 97,5% vs 70%, 66,25% 45%).
Conclusion:
In this study, The CTLA4-1661G>A polymorphism is associated with the incidence of Hepatocellular Carcinoma in chronic hepatitis B patients.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-73. https://doi.org/10.1053/j.gastro.2011.12.061 PMid:22537432 DOI: https://doi.org/10.1053/j.gastro.2011.12.061
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. https://doi.org/10.1038/s41572-020-00240-3 DOI: https://doi.org/10.1038/s41572-020-00240-3
Darmadi D, Ruslie RH. Association between prothrombin induced by Vitamin K absence-II (PIVKA-II) and Barcelona clinic liver cancer (BCLC) stage, tumor size, portal venous thrombosis in hepatocellular carcinoma patients. Sains Malays. 2021;50(2):475-80. http://doi.org/10.17576/jsm-2021-5002-18 DOI: https://doi.org/10.17576/jsm-2021-5002-18
Darmadi D, Ruslie RH, Pakpahan C. Vascular endothelial growth factor levels difference among hepatocellular cancer patients based on Barcelona clinic liver cancer staging. Open Access Maced J Med Sci. 2021;9:797-800. https://doi.org/10.3889/oamjms.2021.6598 DOI: https://doi.org/10.3889/oamjms.2021.6598
Bouqbis L, Izaabel H, Akhayat O, Pérez-Lezaun A, Calafell F, Bertranpetit J, et al. Association of the CTLA4 promoter region (-1661G allele) with Type 1 diabetes in the South Moroccan population. Genes Immun. 2003;4(2):132-7. https://doi.org/10.1038/sj.gene.6363933 DOI: https://doi.org/10.1038/sj.gene.6363933
Gu X, Qi P, Zhou F, Ji Q, Wang H, Dou T, et al. +49G > A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol. 2010;71(1):83-7. https://doi.org/10.1016/j.humimm.2009.09.353 PMid:19778566 DOI: https://doi.org/10.1016/j.humimm.2009.09.353
Ghorbani P, Mollaei HR, Arabzadeh SA, Zahedi MJ. Upregulation of single nucleotide polymorphism of PD-1 gene (rs10204525) in chronic hepatitis B patients. Int Arch Med Microbiol. 2019;2(1):1-8. https://doi.org/10.23937/2643-4008/171000 DOI: https://doi.org/10.23937/2643-4008/1710009
Liu Z, Song Z, Sun J, Sun F, Li C, Sun J, et al. Association between CTLA-4 rs231775 polymorphism and hepatocellular carcinoma susceptibility. Int J Clin Exp Pathol. 2015;8(11):15118-22. PMid:26823853
Wagner M, Jasek M, Karabon L. Immune checkpoint molecules-inherited variations as markers for cancer risk. Front Immunol. 2021;11:606721. https://doi.org/10.3389/fimmu.2020.606721 PMid:33519815 DOI: https://doi.org/10.3389/fimmu.2020.606721
Yang J, Liu J, Chen Y, Tang W, Liu C, Sun Y, et al. Association of CTLA-4 tagging polymorphisms and haplotypes with hepatocellular carcinoma risk: A case-control study. Medicine (Baltimore). 2019;98(29):e16266. https://doi.org/10.1097/md.0000000000016266 PMid:31335675 DOI: https://doi.org/10.1097/MD.0000000000016266
Yan Q, Chen P, Lu A, Zhao P, Gu A. Association between CTLA-4 60G/A and-1661A/G polymorphisms and the risk of cancers: A meta-analysis. PLoS One. 2013;8(12):e83710. https://doi.org/10.1371/journal.pone.0083710 DOI: https://doi.org/10.1371/journal.pone.0083710
Wang L, Li N, Fan X, Wang X, Zhang X, Zhang K, et al. Circulating CTLA-4 levels and CTLA4 polymorphism associate with disease condition and progession and hepatocellular carcinoma patients’ survival in chronic hepatitis B virus infection. Int Immunopharmacol. 2020;82:106377. http://doi.org/10.1016/j.intimp.2020.106377 PMid:32163858 DOI: https://doi.org/10.1016/j.intimp.2020.106377
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Gontar Alamsyah Siregar, Zaimah Z. Tala (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
